Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway
Journal of Cancer · 2024 · 15 (13) · 4328-4344
DOI: 10.7150/jca.96647 ↗At a glance
Journal article in Journal of Cancer, 2024. Written by Yangsheng Wu and 9 co-authors. Institution: College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Cited 13 times so far (Crossref). The full text is freely available in PubMed Central.
Abstract (original language)
Aucun résumé disponible.
Subjects
Author keywords
Authors and institutions
- College of Life Science, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- College of pharmacy, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Hangzhou Traditional Chinese Medicine Hospital, Hangzhou, Zhejiang, China.
- The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China.
- Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Cite
APA
Wu, Y., Dai, S., Zhang, Y., Li, Z., Zhu, B., Liu, Q., Wo, L., Yu, Z., Yuan, X., & Dou, X. (2024). Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway. Journal of Cancer, 15(13), 4328-4344. https://doi.org/10.7150/jca.96647
Vancouver
Wu Y, Dai S, Zhang Y, Li Z, Zhu B, Liu Q, et al. Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway. Journal of Cancer. 2024;15(13):4328-4344. doi:10.7150/jca.96647
BibTeX
@article{Wu2024,
author = {Wu, Yangsheng and Dai, Shijie and Zhang, YuJia and Li, Zheming and Zhu, Bo and Liu, Qingsheng and Wo, Like and Yu, Zhiling and Yuan, Xiaofeng and Dou, Xiaobing},
title = {Atractylenolide II combined with Interferon-γ synergistically ameliorates colorectal cancer progression in vivo and in vitro by blocking the NF-kB p65/PD-L1 pathway},
journal = {Journal of Cancer},
year = {2024},
volume = {15},
number = {13},
pages = {4328--4344},
doi = {10.7150/jca.96647}
}
EUVIMED